List view / Grid view
Dengvaxia was shown to reduce dengue due to all four serotypes in two-thirds of the participants in clinical trials and prevent 8 out of 10 hospitalisations due to dengue and up to 93% of severe dengue cases...
23 December 2015 | By Victoria White
Increasing pressures from customers, drug manufacturers and regulators to convert prescription medications to non-prescription status is one of the main drivers of growth within the market...
23 December 2015 | By Victoria White
The phase 1/2 clinical trial will evaluate Adcetris (brentuximab vedotin) in combination with Opdivo (nivolumab) in patients with CD30-expressing relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas...
23 December 2015 | By Victoria White
According to GlobalData, this rise will be driven by a number of factors, including an increased use of expensive biologics, and off-label use of therapies to treat the disease...
23 December 2015 | By Victoria White
Uptravi (selexipag) acts by relaxing muscles in the walls of blood vessels to dilate (open) blood vessels and decrease the elevated pressure in the vessels supplying blood to the lungs...
23 December 2015 | By Victoria White
The FDA has approved AstraZeneca’s Zurampic (lesinurad) in combination with xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout...
Dengvaxia is the first vaccine licensed for the prevention of dengue in the world...
23 December 2015 | By Victoria White
These new guidelines describe the important features of this disease and provide comprehensive treatment recommendations...
22 December 2015 | By Victoria White
The facility will produce ingredients manufactured using cell cultures and will create more than 400 new jobs in the Austrian capital...
22 December 2015 | By
Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer...
22 December 2015 | By Victoria White
The PPRS is a unique scheme where pharmaceutical companies agreed to contribute towards the cost of medicines, with the aim of making the latest treatments affordable for the NHS...
22 December 2015 | By Victoria White
Enadenotucirev is an oncolytic virus that has been shown in Phase I clinical trials to reach and selectively infect cancer cells when administered by intravenous infusion...
21 December 2015 | By Victoria White
The study enrolled 73 previously-treated patients with severe haemophilia A younger than 12 years of age and assessed the treatment's haemostatic efficacy in prophylaxis and treatment of bleeding episodes...
21 December 2015 | By Victoria White
MSD has announced results from the Phase 2/3 KEYNOTE-010 study of Keytruda (pembrolizumab) in patients with previously treated non-small cell lung cancer (NSCLC)...
21 December 2015 | By Victoria White
BI 1482694 is Boehringer Ingelheim’s 3rd-generation, epidermal growth factor receptor mutation-specific tyrosine kinase inhibitor...
